Human Genome Sciences reports results of mapatumumab Phase 2 trial for multiple myeloma

NewsGuard 100/100 Score
Jun 9 2010

Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with bortezomib (Velcade) in patients with advanced multiple myeloma.

The results showed no difference in disease response or progression-free survival for the combination that included mapatumumab vs. the control group receiving bortezomib alone, and showed that mapatumumab was well tolerated in this study. HGS expects to present the results in full at an appropriate scientific meeting, hopefully later in 2010.

Source:

 Human Genome Sciences

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles
Tea consumption increases bone density and reduces the risk of osteoporosis
Study unlocks genetic secrets in APOEε4 carriers that could defend against Alzheimer's
New tARC-seq method enhances precision in tracking SARS-CoV-2 mutations
Genetic and lifestyle factors linked to brain network aging, study reveals
Does IBD affect cancer risk?
Does vitamin D have protective role against COVID-19?
Persistent COVID-19 could drive virus evolution, new study suggests

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Breakthrough in CRISPR delivery promises safer gene editing